On Nov. 15, 2021, Novavax and SK bioscience announced submission of a Biologics License Application (BLA) for Novavax’ COVID-19 vaccine to South Korea’s Ministry of Food and Drug Safety (MFDS).

p>NVX-CoV2373, Novavax’ recombinant nanoparticle COVID-19 vaccine with Matrix-Mﾙ adjuvant, is the first protein-based COVID-19 vaccine to be submitted for BLA in Korea.